Cibisatamab (CD3E/CEACAM5) - Research Grid Biosimilar

Cibisatamab (CEA-TCB) is T cell bispecific antibody that binds to carcinoembryonic antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab has one single CD3 epsilon chain binding site and two CEA binding sites on T cells (which regulates the binding affinity to cancer cells with high expression of CEA on the cell surface) . This avoids targeting healthy epithelial cells with low CEA expression levels. T cell activation is triggered by binding to CEA on the surface of cancer cells and CD3 on T cells, cytokine secretion and release of cytotoxic particles.

Humanized / CD3E/CEACAM5 [Homo sapiens]

Unconjugated

Primary Antibodies, Biosimilars

CHO cells

Cancer

>95%

Batch dependent

PBS buffer pH7.5

None

Blue Ice

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

IgG1-kappa/lambda with domain crossover

Homo sapiens

CEA TCB, RG-7802, RO-6958688